Merck Sharp & Dohme (I.A.) Corp.  MSD  Caribbean

 

In 1949, scientists working at the Merck Research Laboratories had just discovered cortisone and were on their way to winning the Nobel Prize in Medicine. Closer to home, here in Puerto Rico, MSD Caribbean began its history on November 10, 1949, under the name of Sharp & Dohme Interamerican Corporation with 9 employees.

The modern era of MSD Caribbean began in 1953 when Merck merged with Sharp & Dohme. By 1955 the sales team had increased from 3 to 5 and our human resources totaled 14. In 1966, MSD purchased Charles E. Frosst, greatly increasing our presence in the Caribbean Region.

Located toward the northwest of Puerto Rico are the plants of Merck Sharp & Dohme Química (MSDQ), contributing for over 30 years to the economic progress of the island. First located in Barceloneta, MSDQ manufactured the active ingredient in one of our earliest medications for the treatment of elevated blood pressure. Success in Barceloneta motivated the Company to enlarge its operations to the towns of Caguas in 1987 and Arecibo in 1991. In the last years, MSDQ has continued to expand its manufacturing facilities, strengthening its commitment to Puerto Rico. Many of the products destined for the North American market are manufactured in Puerto Rico.

MSD Caribbean has Marketing and Sales offices located in the Industrial Park, Carolina, Puerto Rico. This office markets all MSD products in Puerto Rico and the adjoining Caribbean Islands (Antigua & Barbuda,
Aruba, Bahamas, Barbados,Bermuda, Cayman Islands, Curacao, Dominican Republic, French Guiana, Guadaloupe, Guyana, Haiti, Jamaica, Martinique, St. Maarten & Bonaire (Netherlands Antilles), Trinidad & Tobago).

For decades, Merck Sharp & Dohme has been an active part of the Puerto Rico community. Today, more than 2,000 employees proudly belong to one of the top pharmaceutical companies in Puerto Rico. Along with the more than 60,000 employees of Merck & Co., Inc. worldwide, we are dedicated to bringing the important discoveries of the Merck research pipeline to the people of Puerto Rico.